Targeting therapy of choroidal neovascularization by use of polypeptide- and PEDF-loaded immunoliposomes under ultrasound exposure

Abstract

Pigment epithelium derived factor (PEDF) has been proven to be an effective drug for the treatment of choroidal neovascularization (CNV). However, the lack of ideal administration route is the biggest bottleneck preventing PEDF from wider clinical use. In this study, we developed a novel PEDF-carrying system which employed immuno-nano-liposomes (INLs) under ultrasound exposure. PEDF-loaded INLs were prepared by conjugating nanoliposomes to the peptide ATWLPPR specifically targeting the receptor-2 for vascular endothelial growth factor (VEGFR-2) and reversely encapsuling PEDF. RF/6A cells were incubated with PEDF-loaded INLs. CNV models of BN rats were injected with PEDF-loaded INLs. MTT assay was used to evaluate the cytotoxicity of the INLs on RF/6A cells. Flow cytometry was conducted to detect the apoptotic rate of cells. Laser scanning confocal microscopy was employed to observe the binding and transmitting process of PEDF-loaded INLs and to calculate the area of CNV in the rat model. The results showed that the PEDF-loaded INLs could exclusively bind to CNV but not to the normal choroidal vessels. The CNV area was significantly decreased in PEDF treatment groups in comparison with control group (P<0.05). Moreover, PEDF-loaded INLs exposed under ultrasound were more efficient in reducing the CNV area (P<0.05). It was concluded that INLs in combination with ultrasonic exposure can transmit PEDF into cytoplasma with high specificity and efficiency, which strengthens the inhibitory effects of PEDF on CNV and reduces its side effects. PEDF-loaded INLs possibly represent a new treatment paradigm for patients with ocular neovascularization.

Keywords

choroidal neovascularization / pigment epithelium derived factor / ultrasound / nanometer / immunoliposome

References

[1] IngoS., LennartB., XiaoyanN., et al.. Modulation of choroidal neovascularization by subretinal injection of retinal pigment epithelium and polystyrene microbeads. Mol Vis, 2009, 15(1): 146-161

[2] MonteroJ.A., Ruiz-MorenoJ.M.. Treatment of choroidal neovascularization in high myopia. Curr Drug Targets, 2010, 11(5): 630-644

[3] DawsonD.W., VolpertO.V., GillisP., et al.. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science, 1999, 285(5425): 245-248

[4] HanY., LiT., ChenD.S., et al.. Prelimanary study of the preparation and character of immunoliposome loading polypeptide PEDF with ATWLPPR as ligand modified on the surface. Chin Hosp Pharm J (Chinese), 2009, 29(22): 1894-1897

[5] ZhaoS., HuangL., WuJ., et al.. Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy. Mol Vis, 2009, 15: 1231-1242

[6] BelgoreF., BlannA., NeilD., et al.. Localization of members of the vascular endothelial growth factor (VEGF) family and their receptors in human atherosclerotic arteries. J Clin Pathol, 2004, 57(3): 266-272

[7] ShoI.Y.. Pigment epithelium-derived factor (PEDF) in health and disease. Curr Mol Med, 2010, 10(3): 258

[8] SheikpranbabuS., RavinarayananH., ElayappanB., et al.. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-and interleukin-1beta-induced vascular permeability and angiogenesis in retinal endothelial cells. Vascul Pharmacol, 2010, 52(1–2): 84-94

[9] UedaS., YamagishiS.I., OkudaS.. Anti-vasopermeability effects of PEDF in retinal-renal disorders. Curr Mol Med, 2010, 10(3): 279-283

[10] YamagishiS.I., MatsuiT.. Anti-atherothrombogenic properties of PEDF. Curr Mol Med, 2010, 10(3): 284-291

[11] WadaM., OgataN., OtsujiT., et al.. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr Eye Res, 1999, 18(3): 203-213

[12] EderM., KrivosheinA.V., BackerM., et al.. ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature. Nucl Med Biol, 2010, 37(4): 405-412

[13] RennoR.Z., TeradaY., HaddadinM.J., et al.. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch Ophthalmol, 2004, 122(7): 1002-1011

[14] CrowderK.C., HughesM.S., MarshJ.N., et al.. Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery. Ultrasound Med Biol, 2005, 31(12): 1693-1700